Retatrutide Body Composition and Lean Mass: What the Evidence Shows

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This evidence deep dive summarizes what the reviewed clinical and summary literature report about retatrutide and body-composition outcomes, with particular attention to whether lean mass (muscle mass) was measured and reported in available trials and reviews. The literature shows large, dose-dependent reductions in body weight and reductions in waist circumference with retatrutide, but direct measurements of lean mass are not reported in the reviewed sources, leaving questions about the composition of that weight loss (fat vs lean tissue).

Summary of weight-loss findings reported in clinical trials

Multiple randomized clinical trials and registrational-phase studies reported large, dose-dependent percent reductions in body weight with once‑weekly subcutaneous retatrutide. A phase 2 trial reported least-squares mean percent weight changes at 24 and 48 weeks ranging from approximately -7% to -24% depending on dose and timepoint versus small changes with placebo, with greater reductions at higher doses and longer follow-up (reported at 24 and 48 weeks) (NEJM phase 2 trial). A separate phase 2 study in people with type 2 diabetes reported dose-dependent percent weight reductions at 36 weeks across maintenance doses including 4 mg, 8 mg, and 12 mg, with the largest reductions seen at the highest doses. A phase 3 randomized trial (TRANSCEND‑T2D‑1) reported mean percent weight changes at week 40 of about -11.5% (4 mg), -13.9% (9 mg), and -15.3% (12 mg) versus -2.6% with placebo. ^{[S2] [S7] [S8]}

Waist circumference and network meta-analysis context

A network meta-analysis that included randomized controlled trials compared retatrutide (8 mg and 12 mg) to other GLP‑1 receptor agonists and polyagonists and reported large estimated reductions in body weight and waist circumference for retatrutide (for example, retatrutide 12 mg: ~-22.1% bodyweight and ~-17.0 cm waist circumference versus placebo in pooled RCT data included through August 30, 2024). ^[S4]

Direct evidence on lean mass or detailed body-composition measures

Across the reviewed phase 2 and phase 3 trial excerpts and the systematic review, outcome reporting centers on percent change in total body weight and waist circumference; specific, direct measures of body composition or lean (muscle) mass (for example, DXA, CT, MRI, or segmental bioimpedance reporting fat mass versus lean mass) are not reported in the reviewed source. ^{[S2] [S7] [S8] [S4] [S1]}

Clinical trial designs, endpoints, and populations relevant to body-composition inference

Key trial characteristics relevant to interpreting weight-related results: the NEJM phase 2 obesity trial randomized adults with BMI ≥30 or BMI 27–<30 plus a weight-related condition to once-weekly subcutaneous retatrutide (multiple maintenance doses including 1 mg, 4 mg, 8 mg, 12 mg with various starting-dose escalation strategies) or placebo for a planned 48-week treatment period, with primary endpoint percent change in body weight at 24 weeks and additional reporting at 48 weeks; a Lancet phase 2 trial in people with type 2 diabetes randomized participants to once-weekly retatrutide (multiple dose arms) or active comparator/placebo with primary glycaemic endpoints at 24 weeks and bodyweight examined at 36 weeks; the TRIUMPH phase 3 program was designed as four randomized, double‑blind studies assessing weekly subcutaneous retatrutide versus placebo across over 5,800 participants with primary weight‑management endpoints defined as percent change in body weight; and a phase 3 trial (TRANSCEND‑T2D‑1) randomized adults with type 2 diabetes to 4 mg, 9 mg, or 12 mg once weekly or placebo with a key secondary endpoint of percent bodyweight change at 40 weeks. ^{[S2] [S7] [S3] [S8]}

Safety signals and outcomes that may affect body composition interpretation

Reviewed trial reports commonly noted dose-related gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) and dose-dependent increases in heart rate that peaked and then declined; these safety and tolerability findings were part of the reported trial results and can influence interpretation of weight change dynamics, but direct links to changes in lean mass were not provided in the reviewed sources. ^{[S2] [S7] [S8]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• Direct measures of body composition (DXA, CT, MRI, or validated segmental bioimpedance) and explicit lean-mass endpoints are not reported in the reviewed sources; conclusions about fat versus lean loss cannot be drawn from percent bodyweight change alone.
• Waist circumference provides a surrogate for central adiposity but does not quantify lean mass.
• Most randomized trial excerpts focus on total bodyweight and metabolic endpoints; longer-term maintenance of weight-loss composition and functional muscle measures (strength, performance) are not described in the reviewed sources.
• The reviewed evidence is dominated by industry‑sponsored trials and pooled RCT data; generalizability to all populations and long-term body-composition outcomes requires further direct measurement and follow-up.

Documentation checklist

• Confirm whether a study reports direct body-composition measurements (DXA, CT, MRI, or validated bioimpedance) before inferring effects on lean mass.
• Distinguish percent bodyweight change from changes in fat mass, visceral adiposity, or lean (muscle) mass when reading trial results.
• When evaluating trials, note dose, treatment duration, and whether a trial used escalation strategies—these are study parameters, not clinical recommendations.
• Look for secondary or exploratory endpoints explicitly measuring lean mass or muscle function (e.g., DXA, appendicular lean mass, handgrip strength).
• Compare waist‑circumference changes as a surrogate for central adiposity but not a direct measure of lean mass.

Related research supplies

• DXA machine calibration log (documentation)
• Clinical study body-composition case report form templates (documentation)
• Temperature-monitoring device for cold-chain sample storage (inventory/labeling)
• Laboratory freezer and sample storage inventory labels

Sources and references

1. [S1] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy.. Biomolecules. 2025. PMID: 40563436. DOI: 10.3390/biom15060796
2. [S2] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.. The New England journal of medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972
3. [S3] Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.. Diabetes, obesity & metabolism. 2026. PMID: 41090431. DOI: 10.1111/dom.70209
4. [S4] Xie Z, Zheng G, Liang Z, Li M, Deng W, Cao W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.. Metabolism: clinical and experimental. 2024. PMID: 39305981. DOI: 10.1016/j.metabol.2024.156038
5. [S5] Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.. Diabetes care. 2024. PMID: 38843460. DOI: 10.2337/dci24-0003
6. [S6] Rubio-Herrera MA, Mera-Carreiro S. Weight management treatment in obesity.. Medicina clinica. 2025. PMID: 40865172. DOI: 10.1016/j.medcli.2025.107152
7. [S7] Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.. Lancet (London, England). 2023. PMID: 37385280. DOI: 10.1016/S0140-6736(23)01053-X
8. [S8] Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). 2026. PMID: 42250575. DOI: 10.1016/S0140-6736(26)00967-0

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.